Jeff Jones
Stock Analyst at Oppenheimer
(0.50)
# 3,820
Out of 4,814 analysts
87
Total ratings
13.33%
Success rate
-26.19%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Outperform | $20 → $19 | $1.24 | +1,438.46% | 3 | Mar 26, 2025 | |
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $14 → $15 | $3.23 | +364.40% | 4 | Mar 26, 2025 | |
| ALMS Alumis | Initiates: Outperform | $32 | $5.06 | +532.41% | 1 | Jan 30, 2025 | |
| EVH Evolent Health | Maintains: Outperform | $28 → $18 | $8.97 | +100.67% | 4 | Jan 24, 2025 | |
| CLRB Cellectar Biosciences | Downgrades: Perform | n/a | $0.30 | - | 5 | Dec 11, 2024 | |
| CATX Perspective Therapeutics | Maintains: Outperform | $22 → $16 | $1.92 | +735.51% | 7 | Nov 22, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Outperform | $23 | $4.69 | +390.41% | 1 | Nov 18, 2024 | |
| CMMB Chemomab Therapeutics | Reiterates: Outperform | $13 → $11 | $1.10 | +900.00% | 7 | Nov 15, 2024 | |
| VTYX Ventyx Biosciences | Reiterates: Outperform | $10 → $9 | $1.08 | +737.21% | 10 | Nov 8, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $52 → $56 | $26.00 | +115.38% | 4 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $35 → $39 | $18.15 | +114.88% | 2 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $87 → $89 | $28.54 | +211.84% | 1 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.46 | +2,982.19% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $6.04 | +1,356.95% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.37 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.25 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $30 | $31.33 | -4.25% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $0.23 | +52,973.86% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.79 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.00 | +1,400.00% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $0.86 | +8,620.93% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $1.30 | +84,515.38% | 2 | Nov 17, 2022 |
Zura Bio
Mar 26, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $1.24
Upside: +1,438.46%
Corvus Pharmaceuticals
Mar 26, 2025
Maintains: Outperform
Price Target: $14 → $15
Current: $3.23
Upside: +364.40%
Alumis
Jan 30, 2025
Initiates: Outperform
Price Target: $32
Current: $5.06
Upside: +532.41%
Evolent Health
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $8.97
Upside: +100.67%
Cellectar Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.30
Upside: -
Perspective Therapeutics
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $1.92
Upside: +735.51%
Y-mAbs Therapeutics
Nov 18, 2024
Initiates: Outperform
Price Target: $23
Current: $4.69
Upside: +390.41%
Chemomab Therapeutics
Nov 15, 2024
Reiterates: Outperform
Price Target: $13 → $11
Current: $1.10
Upside: +900.00%
Ventyx Biosciences
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $1.08
Upside: +737.21%
Kymera Therapeutics
Sep 27, 2024
Maintains: Outperform
Price Target: $52 → $56
Current: $26.00
Upside: +115.38%
Sep 10, 2024
Reiterates: Outperform
Price Target: $35 → $39
Current: $18.15
Upside: +114.88%
Aug 9, 2024
Reiterates: Outperform
Price Target: $87 → $89
Current: $28.54
Upside: +211.84%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.46
Upside: +2,982.19%
Aug 7, 2024
Maintains: Outperform
Price Target: $80 → $88
Current: $6.04
Upside: +1,356.95%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.37
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.25
Upside: -
Feb 29, 2024
Maintains: Neutral
Price Target: $32 → $30
Current: $31.33
Upside: -4.25%
May 25, 2023
Maintains: Outperform
Price Target: $120
Current: $0.23
Upside: +52,973.86%
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $2.79
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.00
Upside: +1,400.00%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $0.86
Upside: +8,620.93%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $1.30
Upside: +84,515.38%